

 **Support for Genome-Wide Association Study** 

Genome-Wide Association Study (GWAS) is a method developed in Japan in 2003 to identify genes associated with diseases, drug efficacy and drug safety.

The powerful method that searches for responsible genes systematically using millions of SNPs is now available not only in academy but also in private companies because of the establishment of SNP database by HapMap project and the development of GWAS chip technology and bioinformatics.

On the other hand, GWAS is also a research that can easily generate erroneous conclusions. For example, in GWAS in which sample sizes are small, the true associations cannot easily be obtained without a deep understanding of the background and the technologies provided from the researchers with sufficient knowledge of medicine and statistical genetics.

StaGen Co. Ltd, a specialized group in medicine, genetics, statistics and informatics, has a plenty of experience in the analyses of GWAS data from academy and pharmaceutical companies.

Future focuses of GWAS include those for rare diseases whose causes are yet unknown and application from research field to real practice, such as new drug development. Please consult us about the analysis of your valuable GWAS data.